

# Luciana Vinti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8523654/publications.pdf>

Version: 2024-02-01

39  
papers

1,171  
citations

471509

17  
h-index

395702

33  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2101  
citing authors

#	ARTICLE	IF	CITATIONS
1	Poor prognosis of B-cell acute lymphoblastic leukemia with <i>TCF7L2</i> / <i>PBX1</i> fusion gene and ovarian involvement at diagnosis: Two case reports and review of the literature. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29299.	1.5	3
2	Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29557.	1.5	5
3	Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience. <i>Cancers</i> , 2022, 14, 1471.	3.7	3
4	Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?. <i>Cancers</i> , 2022, 14, 1703.	3.7	7
5	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. <i>Cancers</i> , 2022, 14, 1540.	3.7	11
6	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. <i>Leukemia</i> , 2022, 36, 1516-1524.	7.2	21
7	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). <i>Blood</i> , 2021, 137, 1582-1590.	1.4	48
8	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 843.	7.4	166
9	Recurrent genetic fusions redefine <i>MLL</i> germ line acute lymphoblastic leukemia in infants. <i>Blood</i> , 2021, 137, 1980-1984.	1.4	12
10	A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma. <i>Hemato</i> , 2021, 2, 264-280.	0.6	0
11	Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience. <i>Diagnostics</i> , 2021, 11, 1594.	2.6	4
12	PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 415-425.	2.0	15
13	Repurposing anthelmintic agents to eradicate resistant leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 72.	6.2	3
14	Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols. <i>Cancers</i> , 2020, 12, 1620.	3.7	10
15	Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2473-2478.	7.2	26
16	Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH97 protocol with/without anti-CD20 administration. <i>British Journal of Haematology</i> , 2020, 189, e108-e111.	2.5	8
17	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. <i>Haematologica</i> , 2019, 104, 1812-1821.	3.5	32
18	Durable remissions in <i>TCF3-HLF</i> positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. <i>Haematologica</i> , 2019, 104, e244-e247.	3.5	52

#	ARTICLE	IF	CITATIONS
19	The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. <i>British Journal of Haematology</i> , 2017, 176, 629-636.	2.5	56
20	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. <i>Blood</i> , 2017, 130, 2146-2149.	1.4	7
21	Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages. <i>Journal of Immunology</i> , 2017, 199, 1516-1525.	0.8	41
22	Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. <i>Oncotarget</i> , 2017, 8, 107886-107898.	1.8	15
23	HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 105957-105970.	1.8	5
24	Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma. <i>Journal of Cancer</i> , 2016, 7, 364-366.	2.5	18
25	Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol. <i>British Journal of Haematology</i> , 2016, 175, 467-475.	2.5	37
26	Cord blood transplantation in children with hemoglobinopathies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1125-1136.	0.8	5
27	Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. <i>British Journal of Haematology</i> , 2015, 170, 826-836.	2.5	23
28	TIM-3/Gal-9 interaction induces IFN $\gamma$ -dependent IDO1 expression in acute myeloid leukemia blast cells. <i>Journal of Hematology and Oncology</i> , 2015, 8, 36.	17.0	42
29	Eltrombopag for treatment of thrombocytopenia-associated disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2243-2256.	1.8	16
30	Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with sickle cell disease. <i>British Journal of Haematology</i> , 2015, 169, 726-736.	2.5	68
31	High frequency of ribosomal protein gene deletions in Italian Diamond-Blackfan anemia patients detected by multiplex ligation-dependent probe amplification assay. <i>Haematologica</i> , 2012, 97, 1813-1817.	3.5	49
32	Chromosome anomalies in bone marrow as primary cause of aplastic or hypoplastic conditions and peripheral cytopenia: disorders due to secondary impairment of RUNX1 and MPL genes. <i>Molecular Cytogenetics</i> , 2012, 5, 39.	0.9	1
33	Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2011, 46, 200-207.	2.4	154
34	Ex vivo expansion of mesenchymal stromal cells. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 73-81.	1.7	76
35	Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 339-349.	1.7	17
36	Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. <i>Haematologica</i> , 2010, 95, 206-213.	3.5	78

#	ARTICLE	IF	CITATIONS
37	The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia. Bone Marrow Transplantation, 2010, 45, 1618-1624.	2.4	21
38	Cord blood transplantation in children with haematological malignancies. Best Practice and Research in Clinical Haematology, 2010, 23, 189-196.	1.7	12
39	Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real-life study. Pediatric Blood and Cancer, 0, , .	1.5	4